Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The search for a vaccine against human immunodeficiency virus type 1 (HIV-1) has many hurdles to overcome. Ideally, the stimulation of both broadly neutralizing antibodies and cell-mediated immune responses remains the best option, but no candidate in clinical trials at present has elicited such antibodies, and efficacy trials have not demonstrated any benefit for vaccines designed to stimulate immune responses of CD8(+) T cells. Findings obtained with the simian immunodeficiency virus (SIV) monkey model have provided new evidence that stimulating effective CD8(+) T cell immunity could provide protection, and in this Perspective we explore the path forward for optimizing such responses in humans.

Original publication

DOI

10.1038/ni.2844

Type

Journal article

Journal

Nat Immunol

Publication Date

04/2014

Volume

15

Pages

319 - 322

Keywords

AIDS Vaccines, Animals, Antigenic Variation, Antigens, Viral, CD8-Positive T-Lymphocytes, Clinical Trials as Topic, Cytotoxicity, Immunologic, HIV Infections, HIV-1, Haplorhini, Humans, Immunization, Immunodominant Epitopes, Protein Engineering, SAIDS Vaccines, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus, Treatment Outcome